Stockreport

European Commission Approves CSL's ANDEMBRY® (garadacimab) for the Prevention of Recurrent Attacks of Hereditary Angioedema (HAE) [Yahoo! Finance]

CSL LTD SP/ADR  (CSLLY) 
NASDAQ:AMEX Investor Relations: csl.com/investors
PDF Thu, February 13, 2025 at 1:00 PM GMT+1 6 min read In This Article CMXHF CSLLY - ANDEMBRY ® , the first and only once-monthly treatment targeting factor XIIa [Read more]